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EDITORIAL
Preventing bone loss after renal transplantation with
bisphosphonates: We can... but should we?
Transplant-associated bone loss and fractures are sig- women with low bone mineral density. Diabetes mellitus
nificant complications associated with kidney, liver, car- and/or kidney/pancreas transplantation are major risk
diac and bone marrow transplantation [1, 2]. The major factors for fractures. The fracture rate is 5%/year in
cause of this condition is treatment with glucocorticoids. patients with pre-existing diabetes mellitus [11, 12] and
Glucocorticoids indirectly affect the skeleton through in kidney/pancreas transplant patients it may be as high
induction of negative calcium balance, secondary hyper- as 12%/year [13–15]. Thus, cumulative fracture preva-
parathyroidism and direct suppression of gonadotropins lence of low trauma fracture over a 5-year period may
with consequent hypogonadism. Their major toxicity, how- be as high as 7 to 11% in nondiabetic renal transplant
ever, is caused by direct inhibition of osteoblastogenesis recipients, and 45 to 49% in insulin-dependent diabetics
nduction of apoptosis in mature osteoblasts and osteoytes following combined pancreas-renal transplantation.
Other immunosuppressive agents, such as cyclosporine As illustrated by the variance in the distribution of
A, may also contribute to bone loss by stimulating bone fractures, there are potential differences between trans-
resorption [4]. Bone histologic analysis in renal trans- plant-associated osteoporosis and postmenopausal bone
plant recipients, however, has failed to identify increased disease that may have both diagnostic and therapeutic
osteoclast-mediated bone resorption [4]. Rather, a low implications. Indeed, in spite of cancellous bone loss,
turnover osteopenia develops following renal transplanta- vertebral fractures are relatively less common following
tion consistent with glucocorticoid-induced suppression renal transplantation, with reported incidence rates of 3
of osteoblast-mediated bone formation [5]. to 10% [11, 13]. Most of the renal transplant-associated
Transplant-associated bone loss occurs predominantly fractures involve the appendicular skeleton. The periph-
at cancellous sites. The initial rate of bone loss is rapid eral distribution of the fractures following renal trans-
and approximates 3 to 8% at the lumbar spine in the plantation also suggests that poor skeletal integrity is
first 6 to 12 months after transplantation [5–7]. The early not merely due to the loss of cancellous bone, but rather
rapid loss correlates with the higher corticosteroid expo- to pre-existing hyperparathyroidism or other factors (that
sure during the initial transplant period. Cross sectional is, neuropathy contributing to foot fractures). In support
and longitudinal studies demonstrate a slower but sig- of this possibility, almost 17% of patients in one cross
nificant rate of lumbar spine bone loss after the first sectional study had fractures before transplantation, sug-
year when glucocorticoid doses are typically lower [8, 9]. gesting pre-existing skeletal vulnerability [12]. The ap-
Additional vertebral bone loss that approximates 1.7% parent discordance between the low rate of vertebral
per year has been observed in the later post-transplant fractures and the lumbar spine osteopenia as assessed
years [10]. Factors contributing to the persistent bone by dual energy X-ray analysis (DEXA) also indicates that
loss may differ from those causing the initial rapid loss bone mineral density may not have the same predictive
of cancellous bone. power in renal transplant recipients as in post-meno-
As with other osteopenic disorders, the reduction in pausal osteoporosis. The effects of renal osteodystrophy,
bone mineral density following renal transplantation is extracellular calcifications and superimposed hypophos-
associated with increased risk of fracture. The yearly phatemic osteomalacia may confound measurement of
rate of fractures in renal transplant recipients is also trabecular and cortical bone volume by DEXA in pa-
much higher than aged matched controls and is influ- tients with renal failure. As a result, additional informa-
enced by a variety of co-morbid conditions. Total frac- tion is needed regarding the utility of BMD in the assess-
ture rates following kidney transplantation are estimated ment of fracture risk in transplant recipients.
to be approximately 2%/year in non-diabetics. Fracture Of the limited number of pharmacological agents
rates are lower in men and higher in post-menopausal available to treat osteoporosis, bisphosphonates are
gaining increasing importance due to their ability to in-
crease bone mineral density and reduce the incidence ofKey words: cancellous bone, post-transplant bone loss, osteopenia,
kidney transplant, bone mineral density. fractures in osteoporotic women [16]. Bisphosphonates
are pyrophosphate analogues that reduce bone resorp-Ó 2000 by the International Society of Nephrology
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tion. In this issue of Kidney International, Fan et al report There are several reasons to be concerned that anti-
resorptive treatment may not prevent fractures in renalthe first randomized, placebo-controlled trial to address
the efficacy of therapy to prevent bone loss immediately transplant recipients. First, the mechanism of bone loss
is different in renal transplant bone disease comparedafter renal transplantation [17]. This study examines the
effectiveness of the intravenous bisphosphonate pami- to postmenopausal osteoporosis, where bisphosphonate
treatment has been shown to reduce the incidence ofdronate in preventing bone loss following renal trans-
plantation. Twenty-six male patients were randomly as- vertebral and nonvertebral fractures [16]. Estrogen defi-
ciency in postmenopausal women is associated with in-signed either to two sequential doses of pamidronate or
saline placebo within one month following renal allograft- creased osteoclast activation and accelerated bone re-
sorption [22]. In contrast, renal transplant patients haveing. Bone mineral density (BMD) was measured by dual
energy X-ray absorptiometry at baseline, 3 and 12 months a low turnover (adynamic-like) bone lesion [5]. Conse-
quently, further suppression of bone remodeling by bis-after transplantation. In the primary outcome measure
of the study, BMD decreased significantly over 12 months phosphonates in renal transplant patients may not im-
prove the mechanical integrity of bone. Second, thein placebo-treated subjects compared with pamidronate-
treated patients. Specifically, BMD decreased 6.4% at pattern of fractures also suggests that the structural fac-
tors contributing to loss of bone strength differ betweenthe lumbar spine and 9% at the femoral neck in the
placebo group, while it remained stable in treated pa- transplant-associated bone disease and other forms of
osteoporosis. In transplant recipients fractures more typ-tients. Results of previous studies also suggest that later
initiation of bisphosphonates may be helpful in renal ically involve the appendicular skeleton, particularly the
feet and ankles, whereas typical osteoporotic fracturetransplant patients. Treatment with oral clodronate for
12 months increased lumbar spine BMD in long-term often involved the axial skeleton and trabecular bone
sites. Thus, stabilization of lumbar BMD after early corti-renal transplant recipients, while it had no effect on
proximal femur density [18]. These data suggest that costeroid-induced bone loss might be linked to the ob-
served low vertebral fracture risk. In any event, there arebisphosphonates may also have positive effects on lum-
bar spine BMD during a period when bone loss is not no prospective randomized studies to date demonstrating
fracture reduction with any bisphosphonate followingrapid and glucocorticoid doses are low.
Only a few other studies to date address the effective- organ transplantation. A reduction in the overall number
of nonvertebral fractures has not been demonstratedness of specific antiresorptive therapies in preventing
bone loss after transplantation. Similar reports of bis- following bisphosphonate treatment of glucocorticoid-
induced osteoporosis [23, 24]. Before recommending thatphosphonate effectiveness in attenuating bone loss have
been reported after cardiac transplantation [19]. In addi- all renal transplant patients receive bisphosphonates, we
need to understand the potential effectiveness of thesetion, etidronate prevents bone loss from the lumbar spine
and proximal femur in men and women treated with agents in preventing fractures in this particular popula-
tion and their potential to have adverse effects on boneglucocorticoids for a variety of other medical conditions
[20]. Alendronate also improves bone density in cortico- remodeling.
In conclusion, bone loss and fractures commonly occursteroid-treated patients, and the gain in BMD is associ-
ated with a reduction in the incidence of morphometric in patients after renal transplantation, particularly in pa-
tients with insulin-dependent diabetes mellitus. Givenvertebral fractures in postmenopausal women [21].
There are several potential limitations regarding the the overall high fracture rate, strong consideration
should be given to primary prevention of this disorder.use of bisphosphonates to treat transplant-associated
bone disease. We have little information on the effective- Moreover, the rapid loss of bone mineral density suggests
that early intervention at the time of transplantationness of bisphosphonates in preventing bone loss in pa-
tients with the highest fracture risk, namely patients with may be the most effective time to initiate preventive
treatment. The results of Fan et al establish that intrave-diabetes mellitus and postmenopausal women. We also
do not know whether to treat all patients or only those nous pamidronate is useful in the prevention of early
bone loss in these patients [17]. Our enthusiasm mustpatients at highest risk for fracture. Other issues, such
as timing of treatment initiation, relative efficacy of oral be tempered, however, by current limitations in our un-
derstanding of the mechanisms responsible for fracturesversus parenteral administration, duration and fre-
quency of treatment, and effectiveness of bisphospho- and the long-term effectiveness of treatment to reduce
fracture rates in this setting. Larger randomized trialsnates in established osteopenia, remain to be proven in
renal transplant patients, as well as in other solid organ are needed to confirm that pamidronate or other bis-
phosphonates reduce the number of fractures in theserecipients. Existing studies are also limited by their small
sample sizes. Finally, large scale trials are needed to patients. Moreover, questions remain regarding the role
of bone mineral density in assessment of individual frac-confirm that treatment with bisphosphonates does in-
deed reduce fracture rates in these populations. ture risk in this population. Until these questions are
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